Preclinical model for evaluating human TCRs against chimeric syngeneic tumors
Background The adoptive cell transfer (ACT) of T cell receptor (TCR)-engineered T cells targeting the HLA-A2-restricted epitope NY-ESO-1157-165 (A2/NY) has yielded important clinical responses against several cancers. A variety of approaches are being taken to augment tumor control by ACT including...
Saved in:
Main Authors: | Olivier Michielin, Philippe Guillaume, Melita Irving, Patrick Reichenbach, Vincent Zoete, Elise Gray-Gaillard, Evangelos Stefanidis, Aikaterini Semilietof, Julien Pujol, Alessia D'Esposito |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2024-12-01
|
Series: | Journal for ImmunoTherapy of Cancer |
Online Access: | https://jitc.bmj.com/content/12/12/e009504.full |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
ATLAS-seq: a microfluidic single-cell TCR screen for antigen-reactive TCRs
by: Siwei Luo, et al.
Published: (2025-01-01) -
Capivasertib enhances chimeric antigen receptor T cell activity in preclinical models of B cell lymphoma
by: Hui-Ju Hsieh, et al.
Published: (2025-03-01) -
Advancements and Future Directions of Dual-Target Chimeric Antigen Receptor T-Cell Therapy in Preclinical and Clinical Studies
by: Chenyun Zhang, et al.
Published: (2025-01-01) -
Antibody-based delivery of interleukin-2 modulates the immunosuppressive tumor microenvironment and achieves cure in pancreatic ductal adenocarcinoma syngeneic mice
by: Carmine Carbone, et al.
Published: (2025-01-01) -
Mouse colorectal cancer organoids: Lessons from syngeneic and orthotopic transplantation systems
by: Yu Muta, et al.
Published: (2025-06-01)